Answers are grounded in this paper and cite their sources.
Nephrotic syndrome (NS) is a life-threatening condition when starting within the 3 months after birth [1–3]. Descriptively, NS is classified as congenital (CNS) when manifesting in utero or during the first three months of life, infantile (INS) with onset later during the first year (4–12 months) and childhood when it develops thereafter [1–3]. CNS may be also described as syndromic or isolated, depending on the presence or not of extrarenal malformations including dysmorphic facial features (e.g. microcephaly) [1–3]. The identification over the last decade of disease-causing mutations in various podocyte-expressed proteins has significantly improved early diagnosis, clinical management and genetic counselling of hereditary CNS [1–3]. Mutations in the gene NPHS1 encoding nephrin were found as the most common cause of CNS [4]. Originally known as the Finnish type of CNS (CNF) [5], this autosomal recessive condition is nowadays preferentially called nephrotic syndrome type 1 (NPHS1) is CNS, due to about 100 distinct mutations found in Finnish as well as non-Finnish cohorts [1–3]. The second most frequent gene causing CNS is the podocin (NPHS2) gene [6], first implicated in sporadic cases of childhood steroid-resistant NS with focal glomerulosclerosis [7]. In a recent large cohort of patients with an isolated NS occurring within the first year of life, two-thirds of the cases were due to mutations in either the NPHS1 or the NPHS2 genes [4]. In the remaining cases, the responsible gene was found to be the transcription factor WT1 (WT1) gene, the laminin-beta 2 (LAMB2) gene or another, non-identified gene [4]. Interestingly, mutations in WT1 and LAMB2 genes have been both associated not only to isolated CNS [4,8] but also to more complex entities including developmental disorders [9] and distinct ocular anomalies (Pierson syndrome) [10]. Lastly, mutations in two additional genes were identified in some cases of nonsyndromic CNS: PLCE1 gene involved in the RAS/MAPK signalling pathway and COQ2 gene involved in the coenzyme Q10 biosynthetic [11,12].
No takes yet. Share an insight, caveat, or question.
Godefroid et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: